Coherus BioSciences, Inc. (CHRS) Downgraded by ValuEngine

ValuEngine cut shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) from a sell rating to a strong sell rating in a report released on Friday.

A number of other equities analysts also recently issued reports on the company. Citigroup Inc. reiterated a buy rating and issued a $23.00 price objective on shares of Coherus BioSciences in a report on Tuesday, November 7th. Zacks Investment Research downgraded Coherus BioSciences from a hold rating to a sell rating in a report on Tuesday, October 10th. Credit Suisse Group reiterated an outperform rating and issued a $17.00 price objective (down previously from $24.00) on shares of Coherus BioSciences in a report on Wednesday, September 27th. Cowen and Company reiterated an outperform rating and issued a $45.00 price objective on shares of Coherus BioSciences in a report on Friday, September 8th. Finally, Maxim Group reiterated a buy rating and issued a $20.00 price objective (down previously from $40.00) on shares of Coherus BioSciences in a report on Friday, September 8th. Three research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Coherus BioSciences has a consensus rating of Buy and an average price target of $31.00.

Coherus BioSciences (NASDAQ CHRS) traded down $0.55 on Friday, reaching $10.05. The company’s stock had a trading volume of 576,100 shares, compared to its average volume of 599,534. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 1.84. Coherus BioSciences has a twelve month low of $10.00 and a twelve month high of $29.59.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus BioSciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities analysts predict that Coherus BioSciences will post -4.39 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Coherus BioSciences, Inc. (CHRS) Downgraded by ValuEngine” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/13/coherus-biosciences-inc-chrs-downgraded-by-valuengine-2.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. Vanguard Group Inc. grew its stake in shares of Coherus BioSciences by 88.8% in the first quarter. Vanguard Group Inc. now owns 2,209,244 shares of the biotechnology company’s stock worth $46,726,000 after acquiring an additional 1,039,402 shares during the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Coherus BioSciences by 54.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock worth $19,964,000 after acquiring an additional 490,899 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of Coherus BioSciences by 70.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,001,104 shares of the biotechnology company’s stock worth $14,366,000 after acquiring an additional 414,229 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Coherus BioSciences in the second quarter worth $4,850,000. Finally, State Street Corp grew its stake in shares of Coherus BioSciences by 26.8% in the second quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock worth $20,329,000 after acquiring an additional 298,986 shares during the last quarter. 69.22% of the stock is currently owned by hedge funds and other institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply